QMBlog Content
Discover More:
// April 01, 2021
COVID-19 Vaccine Handling: Maximizing Doses & Public Confidence...
USP’s COVID-19 Vaccine Handling Toolkit is designed to help address the challenges nurses and other healthcare providers face every day in preparing, distributing and administering essential vaccines.
// March 16, 2021
Quality Raw Materials & Collaboration Essential to mAb COVID-19 Treatment Access in L...
Access to quality raw materials and increased stakeholder collaboration are needed to help ensure availability of monoclonal antibody (mAb) treatments for COVID-19 in low- and middle-income countries (LMICs).
// March 12, 2021
Nitrosamine impurities in medicines: what’s the risk?...
In simple terms, risk is the possibility of something bad happening. It’s the uncertainty around the consequences of an activity with respect to something that we value.
// March 12, 2021
Nitrosamine Impurities in Medicines: Preventing history from repeating itself...
The presence of objectionable levels of chemical impurities in pharmaceuticals can have serious public health impacts. Not only do they pose a risk of harm to patients, but the discovery of unacceptable levels of impurities in trusted medicines can also undermine public confidence in the quality of drug products. Due to the potentially serious risk to public health, impurities in pharmaceuticals are strictly regulated.